NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, BPMC shares have increased by 10.9% and is now trading at $58.11. View which stocks have been mosted impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 1 hold rating, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Blueprint Medicines.

Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Blueprint Medicines.

Blueprint Medicines Corp (NASDAQ:BPMC) released its earnings results on Thursday, February, 13th. The biotechnology company reported ($1.35) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.71) by $0.36. The biotechnology company earned $51.53 million during the quarter, compared to the consensus estimate of $26 million. Blueprint Medicines had a negative net margin of 522.75% and a negative return on equity of 72.52%. The firm's revenue for the quarter was up 4888.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.83) earnings per share. View Blueprint Medicines' earnings history.

13 brokerages have issued twelve-month price targets for Blueprint Medicines' stock. Their forecasts range from $70.00 to $125.00. On average, they anticipate Blueprint Medicines' share price to reach $105.75 in the next year. This suggests a possible upside of 82.0% from the stock's current price. View analysts' price targets for Blueprint Medicines.

Headlines about BPMC stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Blueprint Medicines earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View the latest news aboutBlueprint Medicines.

Blueprint Medicines saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 2,920,000 shares, an increase of 8.6% from the February 13th total of 2,690,000 shares. Based on an average daily trading volume, of 747,600 shares, the short-interest ratio is currently 3.9 days. Approximately 7.0% of the company's stock are short sold. View Blueprint Medicines' Current Options Chain.

Some companies that are related to Blueprint Medicines include Merck KGaA (MKGAF), Genmab A/S (GNMSF), GALAPAGOS NV/S (GLPG), Alnylam Pharmaceuticals (ALNY), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Beigene (BGNE), Mylan (MYL), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO) and ACADIA Pharmaceuticals (ACAD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Amarin (AMRN), Micron Technology (MU), Crispr Therapeutics (CRSP), Nektar Therapeutics (NKTR), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Agile Therapeutics (AGRX) and Intercept Pharmaceuticals (ICPT).

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines' stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Cadian Capital Management LP (4.00%), State Street Corp (3.81%), Alliancebernstein L.P. (2.08%), Norges Bank (1.85%) and Westfield Capital Management Co. LP (1.57%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View institutional ownership trends for Blueprint Medicines.

BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pictet Asset Management Ltd., Perceptive Advisors LLC, BVF Inc. IL, Macquarie Group Ltd., Macquarie Group Ltd., Victory Capital Management Inc., and Westfield Capital Management Co. LP. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch, and Nicholas Lydon. View insider buying and selling activity for Blueprint Medicines.

BPMC stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Cadian Capital Management LP, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Credit Suisse AG, Barclays PLC, Alliancebernstein L.P., and Jane Street Group LLC. View insider buying and selling activity for Blueprint Medicines.

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BPMC stock can currently be purchased for approximately $58.11.

Blueprint Medicines has a market capitalization of $3.14 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe. View additional information about Blueprint Medicines.

The official website for Blueprint Medicines is http://www.blueprintmedicines.com/.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]